Alcobra announces positive results from pre-clinical studies of of its autism treatment MG01C1

|About: Alcobra Ltd. (ADHD)|By:, SA News Editor

Alcobra (ADHD +5.6%) gains after announcing positive findings from a pre-clinical study of MG01CI in a mouse model of Fragile X Syndrome.

The study showed "significant" improvement in both cognitive and social functioning following treatment.

Fragile X syndrome is the most common single-gene cause of autism and inherited cause of intellectual disability among boys.